Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18173604 | 0.87 | LTA4H (0.46) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL27879907 | 0.80 | KMT2A (0.48) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL7792871 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3938851 | 0.79 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1608024 | 0.76 | KMT2A (0.46) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL9310847 | 0.76 | MEN1 (0.46) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL11807023 | 0.76 | TSHR (0.47) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL7067348 | 0.76 | CYP19A1 (0.41) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL7067350 | 0.76 | CYP19A1 (0.41) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL6396731 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043443-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | UNIV CASE WESTERN RESERVE (US) | 2024-02-08 | — | — | US | disclosed |
| US-20210032265-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-04 | — | — | US | disclosed |
| US-20200140453-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-07 | — | — | US | disclosed |
| US-10301320-B2 | Compositions and methods of modulating 15-PGDH activity | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2019-05-28 | — | — | US | disclosed |
| EP-3295940-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | Case Western Reserve University (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9790233-B2 | Compositions and methods of modulating 15-PGDH activity | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2838533-B1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | UNIV CASE WESTERN RESERVE (US) | 2017-10-04 | — | — | EP | disclosed |
| US-20170165241-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-15 | — | — | US | disclosed |
| US-20150072998-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-03-12 | — | — | US | disclosed |
| EP-2838533-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | Case Western Reserve University (US) | 2015-02-25 | — | — | EP | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
| EP-1799218-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | Tibotec Pharmaceuticals Ltd. (IE) | 2007-06-27 | — | — | EP | disclosed |
| US-7223766-B2 | Bi-cyclic pyrimidine inhibitors of TGFβ | SCIOS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223766-B2 | Bi-cyclic pyrimidine inhibitors of TGFβ | SCIOS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223766-B2 | Bi-cyclic pyrimidine inhibitors of TGFβ | SCIOS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| WO-2006035061-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-04-06 | — | — | WO | disclosed |
| EP-1608631-A2 | BI-CYCLIC PYRIMIDINE INHIBITORS OF TGF BETA | SCIOS INC. (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050004143-A1 | Bi-cyclic pyrimidine inhibitors of TGFbeta | SCIOS, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004087056-A2 | BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ | SCIOS INC. (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165241-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | SMN1; SMN2 3855/4885ALDH1A1 415/4885MAPT 4311/4885 |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | UMPS, NUDT1, PNP | SMN1; SMN2 4514/4885ALDH1A1 1844/4885MAPT 3915/4885 |
| US-20200140453-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | SMN1; SMN2 3855/4885ALDH1A1 415/4885MAPT 4311/4885 |
| US-20050004143-A1 | Bi-cyclic pyrimidine inhibitors of TGFbeta | TYMP, TYMS, TGFBR1 | SMN1; SMN2 2652/4885ALDH1A1 2042/4885MAPT 2053/4885 |
| US-20240043443-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | SMN1; SMN2 3855/4885ALDH1A1 415/4885MAPT 4311/4885 |
| US-20150072998-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | SMN1; SMN2 3855/4885ALDH1A1 415/4885MAPT 4311/4885 |
| US-20210032265-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | SMN1; SMN2 3855/4885ALDH1A1 415/4885MAPT 4311/4885 |
| US-10301320-B2 | Compositions and methods of modulating 15-PGDH activity | PTGS1, HPGD, PTGIS | SMN1; SMN2 3855/4885ALDH1A1 415/4885MAPT 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.